Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multiple ascending dose study of LY3056480 in sensorineural hearing loss
2016-004544-10Phase 2Unknown
- Sponsor
- Audion Therapeutics
- Start
- Apr 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of LY3056480 in sensorineural hearing loss (SNHL), sponsored by Audion Therapeutics. Primary endpoint: Change in hearing threshold at week 12 (Part B primary). Status: unknown.
02
Drugs
LY3056480
03
Conditions
sensorineural hearing loss (SNHL)
Beyond the preview
Go deeper on 2016-004544-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004544-10.